Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Chief-Scientific-Officer"

147 News Found

EU greenlights Dupixent for chronic urticaria, offering new hope to patients
Drug Approval | November 27, 2025

EU greenlights Dupixent for chronic urticaria, offering new hope to patients

It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria


Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
Clinical Trials | November 26, 2025

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks


Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials
Clinical Trials | November 25, 2025

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years


Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership
R&D | November 25, 2025

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating


GSK and Fleming Initiative launch bold new fight against antimicrobial resistance
R&D | November 21, 2025

GSK and Fleming Initiative launch bold new fight against antimicrobial resistance

These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections


FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma
Drug Approval | November 12, 2025

FDA grants Orphan Drug Designation for Tinostamustine in malignant glioma

Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition


Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025
Clinical Trials | November 06, 2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg at ObesityWeek 2025

Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively


Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women
Clinical Trials | October 29, 2025

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women


Orion secures license to Abzena’s next-generation cancer antibody
R&D | October 29, 2025

Orion secures license to Abzena’s next-generation cancer antibody

The antibody was designed and developed at Abzena’s Cambridge, UK,


Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders
R&D | October 22, 2025

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation